MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal studies report wide therapeutic window Known interactions Methyl-donor depletion theoretical with chronic dosing (NNMT methylates nicotinamide using SAM) Contraindications Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Not FDA-approved
Ipamorelin is a growth hormone releasing peptide (GHRP) a synthetic compound that mimics ghrelin and signals the pituitary gland to release growth hormone
Tirzepatide tablets and orally disintegrating tablets represent emerging alternatives
This makes it an appealing option for patients who want to avoid the discomfort and downtime of surgery while still achieving significant fat loss
Clinicians managing patients on testosterone who wish to explore retatrutide should: Consult the relevant clinical trial protocols if the patient is enrolled in a study Seek specialist endocrinology input before initiating any off-label or investigational combination Document clinical rationale clearly , obtain informed consent, and follow GMC Good Practice in Prescribing and Managing Medicines and Devices guidance when considering unlicensed or investigational treatments Until formal guidance is available, clinical decision-making should be guided by individual patient riskbenefit assessment, informed consent, and regular monitoring
[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Liu J., Wang Z., Li C., Chen Z., Zheng A., Chang W., Liu G., Cai H